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Protection against cisplatin-
induced nephrotoxicity by a carbon 
monoxide-releasing molecule
Over the last decade, carbon monoxide (CO) has become the 
subject of intense investigation and is emerging as a potential 
therapeutic molecule. CO is produced endogenously during 
cellular metabolism, primarily from the degradation of heme 
by the heme oxygenase enzyme system. CO has been shown to 
ameliorate infl ammation, vascular dysfunction, and transplant 
rejection in several animal models through its vasodilatory, anti-
infl ammatory, antiapoptotic, and immunomodulatory properties. 
Tayem et al. examined the eff ect of a novel water-soluble carbon 
monoxide-releasing molecule (CORM-3) on cisplatin-mediated 
nephrotoxicity (a limiting side-eff ect of this anti cancer agent). 
In the in vitro model, exposure of LLC-PK1 cells treatment with 
CORM-3 resulted in a remarkable and concentration-dependent 
decrease in apoptosis. Th is eff ect involved activation of the cyclic 
3′,5′-guanosine monophosphate pathway. In an in vivo rat model 
of cisplatin-induced renal failure, daily administration of CORM-
3 improved renal function, decreased the number of apoptotic 
tubular cells, and improved the histological profi le. Th ese data 
demonstrate that CORM-3 has potential in the treatment of 
nephrotoxic and ischemia-reperfusion models of renal injury. 
(Am J Physiol Renal Physiol 2006; 290: F789–F794)
Jai Radhakrishnan
Pathways of single gene in distal 
ureteral development are described
Congenital anomalies of the ureter are a major cause of 
chronic renal failure in children. Failure to propel the urine 
into the bladder eff ectively as a result of these malformations 
is thought to be the fi nal common pathway to the hydroureter 
that eventually forms. Th e diversity of structural abnormalities 
seen in such cases, from multiplex kidneys to restricted areas 
of obstruction, derives from the highly ordered and complex 
nature of proper ureteral formation. Airik et al.,1 in an elegant 
series of experiments commented upon by Mendelsohn,2 
demonstrate the dependence of distal ureteral development 
on a single gene, the Tbx18 member of the T-box gene family 
of transcription factors. Th ough animals carrying a null allele 
of Tbx18 die shortly aft er birth with extensive axial skeletal 
abnormalities, it was not until these careful morphological and 
molecular studies on the development of the ureter were done 
that the renal abnormalities were revealed. Remarkably, the 
reciprocal interactions between the ureteric epithelium and 
the surrounding metanephric mesenchyme that characterize 
kidney development in other regions of the kidney are regulated 
by a single gene product confi ned in its expression to this 
region. Th e paper not only reveals the role of the gene in the 
normal development of the smooth muscle cells that line the 
distal urothelium but catalogues the molecular hallmarks of 
that epithelial–mesenchymal interaction precisely. Although 
no associations between mutations in the human Tbx18 and 
malformations of the urinary tract have been described yet, 
detailed studies of the precise pathways served by the gene 
will undoubtedly reveal the etiology and provide clues to 
the treatment and the main causes of hydronephrosis and 
hydroureter in childhood. (1J Clin Invest 2006; 116: 663–674. 
2J Clin Invest 2006; 116: 635–637) 
Robert Safi rstein
Are angiotensin inhibitors more 
renoprotective?
A consensus has emerged that angiotensin-converting enzyme 
(ACE) inhibitors and angiotensin II receptor blockers (ARBs) 
have specifi c renoprotective eff ects. Guidelines specify that 
these are the drugs of choice for the treatment of hypertension 
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in patients with renal disease. JP Casas and colleagues sought 
to determine to what extent this consensus is supported by 
the available evidence in a metaanalysis of published studies.1 
Electronic databases were searched through January 2005 
for randomized trials assessing antihypertensive drugs and 
progression of renal disease. Doubling of creatinine and end-
stage renal disease, and creatinine levels, albuminuria, and 
glomerular fi ltration rates, were calculated with random-eff ect 
models. Th e eff ects of ACE inhibitors or ARBs in placebo-
controlled trials were compared with the eff ects seen in trials 
that used an active comparator drug. Th e authors concluded 
that the benefi ts of ACE inhibitors or ARBs for renal outcomes 
in placebo-controlled trials probably result from a blood-
pressure-lowering eff ect. In patients with diabetes, additional 
renoprotective actions of these substances beyond lowering 
blood pressure remain unproven, and there is uncertainty about 
the greater renoprotection seen in non-diabetic renal disease.
Most studies included in the metaanalysis were published 
before 2002, with one exception: the Antihypertensive and 
Lipid-Lowering Treatment to Prevent Heart Attack Trial 
(ALLHAT).2  Because ALLHAT had a dominating eff ect on 
the metaanalysis, it should be assessed carefully and critically. 
Th e study dealt with high-risk hypertensive patients, including 
12 063 with type 2 diabetes. Urinary excretion of protein or 
albumin was not measured; this precluded correct classifi cation 
of renal disease. Th e renal outcomes were based on a post 
hoc analysis. Th e cause of end-stage renal disease and any 
precipitating clinical circumstances, such as acute renal failure, 
were not assessed. In other words, numerous renal and non-
renal disorders, including drug-related nephrotoxicity, could 
have resulted in end-stage renal disease, in contrast to the 
RENAAL3 and IDNT studies. Th us, the conclusion of Casas and 
colleagues should be interpreted with caution because of the 
heterogeneous patient groups, inconsistencies in the reporting 
of valid trial results, potentially suboptimal doses of ACE 
inhibitors and ARBs, and use of an end point that might have 
been improperly assessed.
Th e commentary by de Zeeuw and colleagues4 stated that the 
study of Casas et al. made a misleading conclusion and would 
be a step backward with respect to good clinical practice and 
have a disastrous result for patients with renal or cardiovascular 
disease if followed by the medical profession. Several trials 
have  proven  that ACE inhibitors and ARBs are associated 
with additive renal protection beyond blood-pressure lowering 
in diabetic and non-diabetic hypertensive patients.5–7 Badly 
designed studies and faulty metaanalyses should not stop us 
from looking at the data as they are: inhibitors of the renin–
angiotensin system off er renal and cardiovascular protection 
beyond blood-pressure control and should be the fi rst-choice 
antihypertensive drugs in guidelines for diabetic and non-
diabetic patients with renal disease and hypertension. 
(1Lancet 2005; 366: 2026–2033. 2Lancet 2006; 367: 898–899. 
3N Engl J Med 2001; 345: 861–869. 4Lancet 2006; 367: 899–900. 
5N Engl J Med 1993; 329: 1456–1462. 6Lancet 1997; 349: 
1857–1863.  7N Engl J Med 2001; 345: 851–860)
Marc De Broe
Intestinal and renal calcium 
oxalate in oxalate homeostasis
Kidney stones are among the most common diseases, with 
an incidence of almost 1% in the population. Although 
the majority of its causes are unknown, genetic factors are 
suspected in most cases. More than 75% of kidney stones 
are composed of calcium oxalate, a salt that is present close 
to or above its level of saturation in the urine. Small changes 
in calcium or oxalate concentration could readily lead to 
the precipitation of stones. Oxalate enters and leaves cells, 
including epithelia, via an oxalate chloride exchanger driven 
by the balance of the concentration gradients of the anions 
across the cell membrane. In the kidney and intestine, it is 
expressed on the apical membrane, where it probably mediates 
oxalate secretion, given that urine chloride is much higher 
than cell chloride. Th e offi  cial mouse-genome name for this 
exchange is SLC26A6. In a new study, Jiang et al. generated 
mice with targeted inactivation of this transporter. Th e mice 
developed a high incidence of calcium oxalate kidney stones 
and hyperoxaluria. Th is fi nding would be counterintuitive if 
the exchanger was supposed to secrete oxalate. It turned out 
that although the urine oxalate concentration in these mice 
was high, so was their plasma oxalate. Hence, the stones and 
hyperoxaluria resulted from fi ltration and concentration in the 
urine. Th e mechanism of high plasma concentration was due to 
a lack of oxalate secretion in the gastrointestinal tract, shown in 
in vitro transport studies on brush border membrane vesicles. 
Th is study also demonstrates the importance of secretion in 
oxalate disposal, as restriction of dietary oxalate greatly reduced 
plasma oxalate concentration. Whether there is renal tubular 
absorption of oxalate remains to be rigorously demonstrated. 
(Nat Genet 2006; 38: 474–478) 
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